Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00877071 · ClinicalTrials.gov registry record · Phase 2

LC Drug Eluting Bead for Treatment of Liver Cancer Which Cannot be Surgically Removed

A Phase 2 study of Hepatocellular Carcinoma, sponsored by University of Pittsburgh.

Completed
Registry status
Phase 2
Development phase
2
Enrollment target
1
Study location

NCT00877071: Completed Phase 2 study of Hepatocellular Carcinoma, sponsored by University of Pittsburgh.

NCT00877071 is a Phase 2 study of Hepatocellular Carcinoma that has completed, run by University of Pittsburgh. The registered enrollment target is 2 participants, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00877071, a Phase 2 study of Hepatocellular Carcinoma, has completed, sponsored by University of Pittsburgh.

COMPLETED
Registry status
Phase 2
Development phase
2 participants
Enrollment target
1
Study location

Study Summary

Advanced HCC represents a high unmet medical need with a poor prognosis and few therapeutic options. Patients who present with HCC beyond the currently accepted Milan criteria are not eligible to be listed for liver transplantation. The proposed study offers local regional therapy to a defined population of patients beyond Milan criteria as an attempt to downstage them to eligibility for liver transplant.

Primary Outcome

Advanced HCC represents a high unmet medical need with a poor prognosis and few therapeutic options. Patients who present with HCC beyond the currently accepted Milan criteria are not eligible to be listed for liver transplantation. The proposed study offers local regional therapy to both a defined population of patients beyond Milan criteria as an attempt to downstage them to eligibility for liver transplant as well as those individuals within Milan criteria as an attempt to maintain their elig

Conditions Studied

Hepatocellular Carcinoma

Interventions

  • DRUG LC Bead loaded with doxorubicin

Study Locations (1)

Pennsylvania

  • UPMC Liver Cancer Center, Montefiore 7 South, 3459 Fifth Avenue - Pittsburgh

Trial Details

FieldValue
Enrollment Target 2 participants
Start Date 2008-11
Est. Completion 2012-04
Phase Phase 2
University of Pittsburgh

1,238 total trials

What the finished NCT00877071 record still lists

NCT00877071 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which LC Bead loaded with doxorubicin is the first listed.

NCT00877071 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT00877071 about?

NCT00877071 is a clinical study titled "LC Drug Eluting Bead for Treatment of Liver Cancer Which Cannot be Surgically Removed". Advanced HCC represents a high unmet medical need with a poor prognosis and few therapeutic options. Patients who present with HCC beyond the currently accepted Milan criteria are not eligible to be listed for liver transplantation. The proposed study offers local regional therapy to a defined popul...

What is the current status of trial NCT00877071?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2008-11. Estimated completion is 2012-04.

What conditions does trial NCT00877071 study?

This clinical trial studies the following conditions: Hepatocellular Carcinoma.

What interventions are being tested in trial NCT00877071?

The interventions under investigation include: LC Bead loaded with doxorubicin (DRUG).

Who is sponsoring clinical trial NCT00877071?

This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00877071 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hepatocellular Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00877071's enrollment target sits among peer trials

2 146th of 145 the lowest of 145 other Hepatocellular Carcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hepatocellular Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00877071, the US trial registry maintained by the National Library of Medicine. NCT00877071 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.